Skip to main content
Top
Published in: International Journal of Hematology 3/2016

01-03-2016 | Original Article

Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice

Authors: Mariko Noguchi-Sasaki, Yusuke Sasaki, Yukari Matsuo-Tezuka, Hideyuki Yasuno, Mitsue Kurasawa, Keigo Yorozu, Yasushi Shimonaka

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

Iron, an essential element for various biological processes, can induce oxidative stress. We hypothesized that iron utilization for erythropoiesis, stimulated by epoetin beta pegol (C.E.R.A.), a long-acting erythropoiesis-stimulating agent, contributes to the reduction of iron-induced oxidative stress. We first investigated the sensitivity of several biomarkers to detect oxidative stress in mice by altering the amount of total body iron; we then investigated whether C.E.R.A. ameliorated oxidative stress through enhanced iron utilization. We treated db/db mice with intravenous iron-dextran and evaluated several biomarkers of iron-induced oxidative stress. In mice loaded with 5 mg/head iron, hepatic iron content was elevated and the oxidative stress marker d-ROMs (serum derivatives of reactive oxygen metabolites) was increased, whereas urinary 8-hydroxy-2′-deoxyguanosine and serum malondialdehyde were not, indicating that d-ROMs is a sensitive marker of iron-induced oxidative stress. To investigate whether C.E.R.A. ameliorated oxidative stress, db/db mice were intravenously administered iron-dextran or dextran only, followed by C.E.R.A. Hemoglobin level increased, while hepatic iron content decreased after C.E.R.A. treatment. Serum d-ROMs decreased after C.E.R.A. treatment in the iron-dextran-treated group. Our results suggest that C.E.R.A. promotes iron utilization for erythropoiesis through mobilization of hepatic iron storage, leading to a decrease in serum oxidative stress markers in iron-loaded db/db mice.
Literature
1.
go back to reference Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G199–203.CrossRefPubMed Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G199–203.CrossRefPubMed
2.
go back to reference Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 2003;531(1–2):81–92.CrossRefPubMed Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 2003;531(1–2):81–92.CrossRefPubMed
4.
5.
6.
go back to reference Ho E. Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol. 2013;1:483–91.PubMedCentralCrossRefPubMed Ho E. Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol. 2013;1:483–91.PubMedCentralCrossRefPubMed
7.
go back to reference Vassalle C, Boni C, Di Cecco P, Landi P. Elevated hydroperoxide levels as a prognostic predictor of mortality in a cohort of patients with cardiovascular disease. Int J Cardiol. 2006;110(3):415–6.CrossRefPubMed Vassalle C, Boni C, Di Cecco P, Landi P. Elevated hydroperoxide levels as a prognostic predictor of mortality in a cohort of patients with cardiovascular disease. Int J Cardiol. 2006;110(3):415–6.CrossRefPubMed
10.
go back to reference Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6(12):699–710.CrossRefPubMed Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6(12):699–710.CrossRefPubMed
11.
go back to reference Vaisman B, Fibach E, Konijn AM. Utilization of intracellular ferritin iron for hemoglobin synthesis in developing human erythroid precursors. Blood. 1997;90(2):831–8.PubMed Vaisman B, Fibach E, Konijn AM. Utilization of intracellular ferritin iron for hemoglobin synthesis in developing human erythroid precursors. Blood. 1997;90(2):831–8.PubMed
12.
go back to reference Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21(24):4033–8.CrossRefPubMed Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21(24):4033–8.CrossRefPubMed
13.
go back to reference Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012;96(6):692–700.CrossRefPubMed Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012;96(6):692–700.CrossRefPubMed
14.
go back to reference Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, Matsumoto-Omori Y, Kurasawa M, Yorozu K, et al. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol. 2014;99(5):561–9.CrossRefPubMed Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, Matsumoto-Omori Y, Kurasawa M, Yorozu K, et al. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol. 2014;99(5):561–9.CrossRefPubMed
15.
go back to reference Ikeda Y, Enomoto H, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, et al. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol. 2013;304(7):F1028–36.CrossRefPubMed Ikeda Y, Enomoto H, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, et al. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol. 2013;304(7):F1028–36.CrossRefPubMed
16.
go back to reference Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy. Survey of ophthalmology. 2015. Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy. Survey of ophthalmology. 2015.
18.
go back to reference Vassalle C, Bianchi S, Battaglia D, Landi P, Bianchi F, Carpeggiani C. Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J Atheroscler Thromb. 2012;19(8):712–7.PubMed Vassalle C, Bianchi S, Battaglia D, Landi P, Bianchi F, Carpeggiani C. Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J Atheroscler Thromb. 2012;19(8):712–7.PubMed
19.
go back to reference Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25 Suppl 1):IV6–19. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25 Suppl 1):IV6–19.
20.
go back to reference Ishizaka Y, Yamakado M, Toda A, Tani M, Ishizaka N. Relationship between estimated glomerular filtration rate, albuminuria, and oxidant status in the Japanese population. BMC Nephrol. 2013;14:191.PubMedCentralCrossRefPubMed Ishizaka Y, Yamakado M, Toda A, Tani M, Ishizaka N. Relationship between estimated glomerular filtration rate, albuminuria, and oxidant status in the Japanese population. BMC Nephrol. 2013;14:191.PubMedCentralCrossRefPubMed
21.
go back to reference Coaccioli S, Standoli ML, Biondi R, Panaccione A, Landucci P, Del Giorno R, et al. Assessment of the oxidative stress markers in patients with chronic renal insufficiency undergoing dialysis treatment. Clin Ter. 2010;161(5):441–4.PubMed Coaccioli S, Standoli ML, Biondi R, Panaccione A, Landucci P, Del Giorno R, et al. Assessment of the oxidative stress markers in patients with chronic renal insufficiency undergoing dialysis treatment. Clin Ter. 2010;161(5):441–4.PubMed
22.
go back to reference Ishizaka Y, Yamakado M, Toda A, Tani M, Ishizaka N. Relationship between serum uric acid and serum oxidative stress markers in the Japanese general population. Nephron Clin Pract. 2014;128(1–2):49–56.CrossRefPubMed Ishizaka Y, Yamakado M, Toda A, Tani M, Ishizaka N. Relationship between serum uric acid and serum oxidative stress markers in the Japanese general population. Nephron Clin Pract. 2014;128(1–2):49–56.CrossRefPubMed
23.
go back to reference Samouilidou E, Grapsa E, Karpouza A, Lagouranis A. Reactive oxygen metabolites: a link between oxidative stress and inflammation in patients on hemodialysis. Blood Purif. 2007;25(2):175–8.CrossRefPubMed Samouilidou E, Grapsa E, Karpouza A, Lagouranis A. Reactive oxygen metabolites: a link between oxidative stress and inflammation in patients on hemodialysis. Blood Purif. 2007;25(2):175–8.CrossRefPubMed
25.
go back to reference Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2):149–59.CrossRefPubMed Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2):149–59.CrossRefPubMed
26.
go back to reference Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3.CrossRefPubMed Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3.CrossRefPubMed
27.
28.
go back to reference Glass J, Lavidor LM, Robinson SH. Studies of murine erythroid cell development. Synthesis of heme and hemoglobin. J Cell Biol. 1975;65(2):298–308.CrossRefPubMed Glass J, Lavidor LM, Robinson SH. Studies of murine erythroid cell development. Synthesis of heme and hemoglobin. J Cell Biol. 1975;65(2):298–308.CrossRefPubMed
29.
30.
go back to reference Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84.PubMedCentralCrossRefPubMed Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84.PubMedCentralCrossRefPubMed
32.
go back to reference Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial. 2014;18(5):414–20.CrossRefPubMed Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial. 2014;18(5):414–20.CrossRefPubMed
33.
go back to reference Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apher Dial. 2014;18(5):421–6.CrossRefPubMed Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apher Dial. 2014;18(5):421–6.CrossRefPubMed
34.
go back to reference Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004;43(6):1030–9.CrossRefPubMed Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004;43(6):1030–9.CrossRefPubMed
35.
go back to reference Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2495–501.CrossRefPubMed Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2495–501.CrossRefPubMed
36.
go back to reference Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005;106(12):3710–7.CrossRefPubMed Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005;106(12):3710–7.CrossRefPubMed
37.
go back to reference Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001;37(3):564–72.CrossRefPubMed Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001;37(3):564–72.CrossRefPubMed
38.
go back to reference Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, et al. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010;14(4):349–55.CrossRefPubMed Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, et al. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010;14(4):349–55.CrossRefPubMed
39.
go back to reference Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534–40.CrossRefPubMed Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534–40.CrossRefPubMed
40.
go back to reference van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28(12):3062–71.CrossRefPubMed van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28(12):3062–71.CrossRefPubMed
Metadata
Title
Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice
Authors
Mariko Noguchi-Sasaki
Yusuke Sasaki
Yukari Matsuo-Tezuka
Hideyuki Yasuno
Mitsue Kurasawa
Keigo Yorozu
Yasushi Shimonaka
Publication date
01-03-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1929-3

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine